|
Although the importance of amyloid in
the pathophysiology of AD
is controversial, it is currently the main target for early
diagnosis
through cerebrospinal fluid analysis (Fagan et al ),
brain imaging (Mintun et al ) and treatment (Aisen et
al ).
[11C]PIB
in a nondemented population: potential antecedent marker of
Alzheimer disease
(NEUROLOGY 2006;67:446-452)
MARK A. MINTuN, MD,
G.N. LAROSSA,
Y.I. SHELINE, MD,
C.S. DENCE, MS
ET AL,
pittsburgh, pa,
st. louis, mo
Inverse relation between in vivo
amyloid imaging load and cerebrospinal fluid Aß42
in humans
(ANN NEUROL 2006;59:512-519)
ANNE M. FAGAN, PHD,
MARK A. MINTUN, MD,
ROBERT H. MACH, PHD,
SANG-YOON LEE, PHD,
ET AL,
ST. LOUIS, Mo
A Phase II study targeting amyloid-ß
with 3APS in mild-to-moderate Alzheimer disease
(NEUROLOGY 2006;67:1757-1763)
P.S. AISEN, MD,
D. SAUMIER, PHD,
R. BRIAND, PHD,
J. LAURIN, PHD,
ET AL
WASHINGTON, dc,
LAVAL, QC
|
